Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use.
School of Pharmacy and Biomedical Science, Curtin University, Perth, WA, Australia.
Curtin Health Innovation Research Institute, Perth, WA, Australia.
- Published Article
The Journal of pharmacy and pharmacology
- Publication Date
Mar 01, 2018
Doxorubicin-induced damage to MSCs is of concern clinically. However, MSCs also have been associated with resistance of tumour cells to drugs including doxorubicin. Further studies, particularly in vivo, are needed to provide consistent results of how the doxorubicin-induced changes to MSCs affect treatment and patient health.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/29355940